Annual CFI
$15.54 M
+$38.82 M+166.77%
31 December 2023
Summary:
Corvus Pharmaceuticals annual cash flow from investing activities is currently $15.54 million, with the most recent change of +$38.82 million (+166.77%) on 31 December 2023. During the last 3 years, it has fallen by -$6.02 million (-27.92%). CRVS annual CFI is now -81.68% below its all-time high of $84.83 million, reached on 31 December 2017.CRVS Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$3.89 M
+$13.61 M+77.78%
30 September 2024
Summary:
Corvus Pharmaceuticals quarterly cash flow from investing activities is currently -$3.89 million, with the most recent change of +$13.61 million (+77.78%) on 30 September 2024. Over the past year, it has dropped by -$1.57 million (-67.82%). CRVS quarterly CFI is now -111.01% below its all-time high of $35.32 million, reached on 30 June 2017.CRVS Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$23.72 M
-$21.44 M-938.94%
30 September 2024
Summary:
Corvus Pharmaceuticals TTM cash flow from investing activities is currently -$23.72 million, with the most recent change of -$21.44 million (-938.94%) on 30 September 2024. Over the past year, it has dropped by -$39.26 million (-252.62%). CRVS TTM CFI is now -127.96% below its all-time high of $84.83 million, reached on 31 December 2017.CRVS TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRVS Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -67.8% | -252.6% |
| 3 y3 years | -27.9% | -94.6% | -210.0% |
| 5 y5 years | +377.4% | -184.7% | -828.7% |
CRVS Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -27.9% | +166.8% | -122.2% | +84.8% | -210.0% | at low |
| 5 y | 5 years | -65.3% | +166.8% | -114.0% | +84.8% | -148.5% | at low |
| alltime | all time | -81.7% | +116.9% | -111.0% | +94.5% | -128.0% | +84.2% |
Corvus Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.89 M(-77.8%) | -$23.72 M(+938.9%) |
| June 2024 | - | -$17.50 M(>+9900.0%) | -$2.28 M(-120.9%) |
| Mar 2024 | - | -$7000.00(-99.7%) | $10.93 M(-29.7%) |
| Dec 2023 | $15.54 M(-166.8%) | -$2.32 M(-113.2%) | $15.54 M(+11.2%) |
| Sept 2023 | - | $17.55 M(-509.1%) | $13.98 M(-2742.2%) |
| June 2023 | - | -$4.29 M(-193.2%) | -$529.00 K(-107.7%) |
| Mar 2023 | - | $4.60 M(-218.5%) | $6.90 M(-129.6%) |
| Dec 2022 | -$23.28 M(-208.0%) | -$3.88 M(-227.7%) | -$23.28 M(+8.8%) |
| Sept 2022 | - | $3.04 M(-3.2%) | -$21.39 M(+2.1%) |
| June 2022 | - | $3.14 M(-112.3%) | -$20.96 M(+136.6%) |
| Mar 2022 | - | -$25.57 M(+1179.3%) | -$8.86 M(-141.1%) |
| Dec 2021 | $21.56 M(-51.8%) | -$2.00 M(-157.6%) | $21.56 M(-10.2%) |
| Sept 2021 | - | $3.47 M(-77.2%) | $24.02 M(-21.2%) |
| June 2021 | - | $15.24 M(+214.5%) | $30.49 M(+39.1%) |
| Mar 2021 | - | $4.85 M(+946.7%) | $21.92 M(-51.0%) |
| Dec 2020 | $44.77 M(+1275.4%) | $463.00 K(-95.3%) | $44.77 M(-8.4%) |
| Sept 2020 | - | $9.94 M(+49.0%) | $48.90 M(+72.0%) |
| June 2020 | - | $6.67 M(-75.9%) | $28.44 M(+28.2%) |
| Mar 2020 | - | $27.70 M(+502.8%) | $22.18 M(+581.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | $3.25 M(-110.8%) | $4.59 M(-143.7%) | $3.25 M(-37.3%) |
| Sept 2019 | - | -$10.53 M(-2630.0%) | $5.19 M(-86.7%) |
| June 2019 | - | $416.00 K(-95.3%) | $39.03 M(-255.8%) |
| Mar 2019 | - | $8.77 M(+34.2%) | -$25.04 M(-17.1%) |
| Dec 2018 | -$30.19 M(-135.6%) | $6.53 M(-72.0%) | -$30.19 M(+15.9%) |
| Sept 2018 | - | $23.31 M(-136.6%) | -$26.05 M(-9.2%) |
| June 2018 | - | -$63.66 M(-1858.5%) | -$28.71 M(-140.9%) |
| Mar 2018 | - | $3.62 M(-66.1%) | $70.27 M(-17.2%) |
| Dec 2017 | $84.83 M(-299.3%) | $10.67 M(-48.3%) | $84.83 M(+2.2%) |
| Sept 2017 | - | $20.66 M(-41.5%) | $83.03 M(+18.1%) |
| June 2017 | - | $35.32 M(+94.3%) | $70.29 M(+104.5%) |
| Mar 2017 | - | $18.18 M(+104.7%) | $34.37 M(-180.8%) |
| Dec 2016 | -$42.56 M(-53.8%) | $8.88 M(+12.1%) | -$42.56 M(-65.2%) |
| Sept 2016 | - | $7.92 M(-1408.8%) | -$122.26 M(-2.0%) |
| June 2016 | - | -$605.00 K(-99.0%) | -$124.78 M(-17.1%) |
| Mar 2016 | - | -$58.75 M(-17.1%) | -$150.46 M(+63.5%) |
| Dec 2015 | -$92.03 M | -$70.83 M(-1413.1%) | -$92.03 M(+334.0%) |
| Sept 2015 | - | $5.39 M(-120.5%) | -$21.20 M(-20.3%) |
| June 2015 | - | -$26.27 M(+8009.6%) | -$26.60 M(+8109.6%) |
| Mar 2015 | - | -$324.00 K | -$324.00 K |
FAQ
- What is Corvus Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Corvus Pharmaceuticals?
- What is Corvus Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Corvus Pharmaceuticals?
- What is Corvus Pharmaceuticals quarterly CFI year-on-year change?
- What is Corvus Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for Corvus Pharmaceuticals?
- What is Corvus Pharmaceuticals TTM CFI year-on-year change?
What is Corvus Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of CRVS is $15.54 M
What is the all time high annual CFI for Corvus Pharmaceuticals?
Corvus Pharmaceuticals all-time high annual cash flow from investing activities is $84.83 M
What is Corvus Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of CRVS is -$3.89 M
What is the all time high quarterly CFI for Corvus Pharmaceuticals?
Corvus Pharmaceuticals all-time high quarterly cash flow from investing activities is $35.32 M
What is Corvus Pharmaceuticals quarterly CFI year-on-year change?
Over the past year, CRVS quarterly cash flow from investing activities has changed by -$1.57 M (-67.82%)
What is Corvus Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of CRVS is -$23.72 M
What is the all time high TTM CFI for Corvus Pharmaceuticals?
Corvus Pharmaceuticals all-time high TTM cash flow from investing activities is $84.83 M
What is Corvus Pharmaceuticals TTM CFI year-on-year change?
Over the past year, CRVS TTM cash flow from investing activities has changed by -$39.26 M (-252.62%)